Limited data are available to guide cardiovascular screening in adult or masters athletes (≥35 years old). This review provides recommendations and the rationale for the cardiovascular risk assessment of older athletes.
Evidence Acquisition:
Review of available clinical guidelines, original investigations, and additional searches across PubMed for articles relevant to cardiovascular screening, risk assessment, and prevention in adult athletes (1990-2020).
Study Design:
Clinical review.
Level of Evidence:
Level 3.
Results:
Atherosclerotic coronary artery disease (CAD) is the leading cause of exercise-induced acute coronary syndromes, myocardial infarction, and sudden cardiac death in older athletes. Approximately 50% of adult patients who experience acute coronary syndromes and sudden cardiac arrest do not have prodromal symptoms of myocardial ischemia. The risk of atherosclerotic cardiovascular disease (ASCVD) can be estimated by using existing risk calculators. ASCVD 10-year risk is stratified into 3 categories: low-risk (≤10%), intermediate-risk (between 10% and 20%), and high-risk (≥20%). Coronary artery calcium (CAC) scoring with noncontrast computed tomography provides a noninvasive measure of subclinical CAD. Evidence supports a significant association between elevated CAC and the risk of future cardiovascular events, independent of traditional risk factors or symptoms. Statin therapy is recommended for primary prevention if 10-year ASCVD risk is ≥10% (intermediate- or high-risk patients) or if the Agatston score is >100 or >75th percentile for age and sex. Routine stress testing in asymptomatic, low-risk patients is not recommended.
Conclusion:
We propose a comprehensive risk assessment for older athletes that combines conventional and novel risk factors for ASCVD, a 12-lead resting electrocardiogram, and a CAC score. Available risk calculators provide a 10-year estimate of ASCVD risk allowing for risk stratification and targeted management strategies. CAC scoring can refine risk estimates to improve the selection of patients for initiation or avoidance of pharmacological therapy.
AengevaerenVLMosterdABraberTL, et al. Relationship between lifelong exercise volume and coronary atherosclerosis in athletes. Circulation. 2017;136:138-148.
2.
AlbertCMMittlemanMAChaeCULeeIMHennekensCHMansonJE.Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med. 2000;343:1355-1361.
3.
American Academy of Family Physicians, American Academy of Pediatrics, American College of Sports Medicine, et al. Preparticipation Physical Evaluation. 4th ed.American Academy of Pediatrics; 2010.
4.
ArnettDKBlumenthalRSAlbertMA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:1376-1414.
5.
ASCEND Study Collaborative Group, BowmanLMafhamM, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-1539.
6.
BanachMSerbanCSahebkarA, et al; Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90:24-34.
7.
ChiavaroliLNishiSKKhanTA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. Prog Cardiovasc Dis. 2018;61:43-53.
8.
ChouRDanaTBlazinaI, et al. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality; 2016.
9.
CookNRPaynterNPEatonCB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation. 2012;125:1748-1756, S1-11.
10.
CorradoDBassoCRizzoliGSchiavonMThieneG.Does sports activity enhance the risk of sudden death in adolescents and young adults?J Am Coll Cardiol. 2003;42:1959-1963.
11.
CorradoDPellicciaABjørnstadHH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:516-524.
12.
CromwellWCOtvosJDKeyesMJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—implications for LDL management. J Clin Lipidol. 2007;1:583-592.
13.
DeFilippisAPYoungRCarrubbaCJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266-275.
14.
DeFinaLFRadfordNBBarlowCE, et al. Association of all-cause and cardiovascular mortality with high levels of physical activity and concurrent coronary artery calcification. JAMA Cardiol. 2019;4:174-181.
15.
DreznerJAO’ConnorFGHarmonKG, et al. AMSSM Position Statement on Cardiovascular Preparticipation Screening in Athletes: current evidence, knowledge gaps, recommendations and future directions. Br J Sports Med. 2017;51:153-167.
16.
DreznerJASharmaSBaggishA, et al. International criteria for electrocardiographic interpretation in athletes: consensus statement. Br J Sports Med. 2017;51:704-731.
17.
EckartREShryEABurkeAP, et al; Department of Defense Cardiovascular Death Registry Group. Sudden death in young adults an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol. 2011;58:1254-1261.
18.
Emerging Risk Factors Collaboration, Di AngelantonioESarwarN, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
19.
Emerging Risk Factors Collaboration, ErqouSKaptogeS, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302412-423.
20.
Emerging Risk Factors Collaboration, KaptogeSDi AngelantonioE, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
21.
Emerging Risk Factors Collaboration, KaptogeSDi AngelantonioE, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320.
22.
EstruchRRosESalas-SalvadóJ, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl JMed. 2018;378:e34.
23.
FinocchiaroGPapadakisMRobertusJL, et al. Etiology of sudden death in sports: insights from a United Kingdom regional registry. J Am Coll Cardiol. 2016;67:2108-2115.
24.
FletcherGFAdesPAKligfieldP, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128:873-934.
25.
GazianoJMBrotonsCCoppolecchiaR, et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036-1046.
26.
GiriSThompsonPDKiernanFJ, et al. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. JAMA. 1999;282:1731-1736.
27.
GoffDCJrLloyd-JonesDMBennettG, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2935-2959.
28.
GrundySMStoneNJBaileyAL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-e1143.
29.
HarmonKGAsifIMMaleszewskiJJ, et al. Incidence, cause, and comparative frequency of sudden cardiac death in National Collegiate Athletic Association athletes: a decade in review. Circulation. 2015;132:10-19.
30.
HechtHSCroninPBlahaMJ, et al. 2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology. J Thorac Imaging. 2017;32:W54-W66.
31.
HlatkyMAGreenlandPArnettDK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.
32.
HouZHLuBGaoY, et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovasc Imaging. 2012;5:990-999.
33.
HussainNGershBJGonzalez CartaK, et al. Impact of cardiorespiratory fitness on frequency of atrial fibrillation, stroke, and all-cause mortality. Am J Cardiol. 2018;121:41-49.
34.
JacobsonTA.Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc. 2013;88:1294-1311.
35.
JacobsonTAItoMKMakiKC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9:129-169.
36.
JuraschekSPBlahaMJBlumenthalRS, et al. Cardiorespiratory fitness and incident diabetes: the FIT (Henry Ford ExercIse Testing) project. Diabetes Care. 2015;38:1075-1081.
37.
JuraschekSPBlahaMJWheltonSP, et al. Physical fitness and hypertension in a population at risk for cardiovascular disease: the Henry Ford ExercIse Testing (FIT) project. J Am Heart Assoc. 2014;3:e001268.
38.
KheraABudoffMJO’DonnellCJ, et al. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) coronary calcium atherosclerotic cardiovascular disease risk calculator. Circulation. 2018;138:1819-1827.
39.
KimJHMalhotraRChiampasG, et al. Cardiac arrest during long-distance running races. N Engl J Med. 2012;366:130-140.
40.
KyuHHBachmanVFAlexanderLT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ. 2016;354:i3857.
41.
Lloyd-JonesDMBraunLTNdumeleCE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019;73:3153-3167.
42.
MachFBaigentCCatapanoAL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.
43.
MandsagerKHarbSCremerPPhelanDNissenSEJaberW.Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1:e183605.
44.
ManickamPRathodAPanaichS, et al. Comparative prognostic utility of conventional and novel lipid parameters for cardiovascular disease risk prediction: do novel lipid parameters offer an advantage?J Clin Lipidol. 2011;5:82-90.
45.
MarijonETaffletMCelermajerDS, et al. Sports-related sudden death in the general population. Circulation. 2011;124:672-681.
46.
MarijonEUy-EvanadoADumasF, et al. Warning symptoms are associated with survival from sudden cardiac arrest. Ann Intern Med. 2016;164:23-29.
47.
MaronBJDoererJJHaasTSTierneyDMMuellerFO.Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085-1092.
48.
MaronBJFriedmanRAKligfieldP, et al. Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2014;64:1479-1514.
49.
MaronBJLevineBDWashingtonRL, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 2: preparticipation screening for cardiovascular disease in competitive athletes: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66:2356-2361.
50.
McClellandRLJorgensenNWBudoffM, et al. 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643-1653.
51.
MerghaniAMaestriniVRosminiS, et al. Prevalence of subclinical coronary artery disease in masters endurance athletes with a low atherosclerotic risk profile. Circulation. 2017;136:126-137.
52.
MitchellJDFergestromNGageBF, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J Am Coll Cardiol. 2018;72:3233-3242.
53.
MittlemanMAMaclureMToflerGHSherwoodJBGoldbergRJMullerJE.Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med. 1993;329:1677-1683.
54.
MoraSWengerNKCookNR, et al. Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women’s Health Initiative. JAMA Intern Med. 2018;178:1231-1240.
55.
MuntnerPColantonioLDCushmanM, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406-1415.
NoakesTDOpieLHRoseAGKleynhansPHSchepersNJDowdeswellR.Autopsy-proved coronary atherosclerosis in marathon runners. N Engl J Med. 1979;301:86-89.
58.
O’DonoghueMLFazioSGiuglianoRP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483-1492.
59.
OtvosJDMoraSShalaurovaIGreenlandPMackeyRHGoffDCJr.Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105-113.
PetersonDFSiebertDMKuceraKL, et al. Etiology of sudden cardiac arrest and death in US competitive athletes: a 2-year prospective surveillance study. Clin J Sport Med. 2020;30:305-314.
62.
PowellKEKingACBuchnerDM, et al. The scientific foundation for the physical activity guidelines for Americans, 2nd edition.J Phys Act Health. 2018:1-11.
63.
QuHGuoMChaiHWangWTGaoZYShiDZ.Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e009835.
64.
RaalFJGiuglianoRPSabatineMS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63:1278-1288.
65.
RadfordNBDeFinaLFLeonardD, et al. Cardiorespiratory fitness, coronary artery calcium, and cardiovascular disease events in a cohort of generally healthy middle-age men: results from the Cooper Center Longitudinal Study. Circulation. 2018;137:1888-1895.
66.
RanaJSTabadaGHSolomonMD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016;67:2118-2130.
67.
RidkerPM.Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-369.
68.
RidkerPMBuringJERifaiNCookNR.Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-619.
69.
RidkerPMDanielsonEFonsecaFA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
70.
RidkerPMEverettBMThurenT, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-1131.
71.
RidkerPMMacFadyenJGFonsecaFA, et al; JUPITER Study Group. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009;2:616-623.
72.
RidkerPMPaynterNPRifaiNGazianoJMCookNR.C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243-2251.
ShahRVMurthyVLColangeloLA, et al. Association of fitness in young adulthood with survival and cardiovascular risk: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Intern Med. 2016;176:87-95.
75.
ShiromaEJLeeIM.Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;122:743-752.
76.
SiscovickDSWeissNSFletcherRHLaskyT.The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med. 1984;311:874-877.
77.
ThompsonPD.Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005;112:2354-2363.
78.
ThompsonPDFunkEJCarletonRASturnerWQ.Incidence of death during jogging in Rhode Island from 1975 through 1980. JAMA. 1982;247: 2535-2538.
79.
TsimikasS.A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692-711.
80.
VainshelboimBMullerJLimaRM, et al. Cardiorespiratory fitness and cancer incidence in men. Ann Epidemiol. 2017;27:442-447.
81.
van de SandeDABreuerMAKempsHM.Utility of exercise electrocardiography in pre-participation screening in asymptomatic athletes: a systematic review. Sports Med. 2016;46:1155-1164.
82.
van der AalstCMDenissenSJAMVonderM, et al. Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. Eur Heart J Cardiovasc Imaging. 2020.
83.
WallerBFRobertsWC.Sudden death while running in conditioned runners aged 40 years or over. Am J Cardiol. 1980;45:1292-1300.
84.
WheltonPKCareyRMAronowWS, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269-1324.
85.
WilsonPWD’AgostinoRBLevyDBelangerAMSilbershatzHKannelWB.Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
86.
WolkMJBaileySRDohertyJU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;63:380-406.
